RxDoctor Payments Data

Casey Gayer, PA

Physician Assistant · Massillon, OHNPI 1922288596

Payments from drug & device makers

$10,497in general payments, 2019–2025

Across 455 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • SK Life Science, Inc.$851
  • AstraZeneca$597
  • Lilly USA, LLC$560
  • Lundbeck LLC$521
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$10,24598%
  • Education$2522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,497 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$15,661
Medicare patients
99
Services billed
576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate389$404,205
UbrelvyUbrogepant220$281,230
Emgality PenGalcanezumab-Gnlm275$240,979
Ajovy AutoinjectorFremanezumab-Vfrm112$99,141
Aimovig AutoinjectorErenumab-Aooe104$91,984
BotoxOnabotulinumtoxina45$56,063
QuliptaAtogepant37$46,325
BriviactBrivaracetam22$32,472
VyeptiEptinezumab-Jjmr15$29,826
XcopriCenobamate12$20,595
NeuproRotigotine19$19,463
ZavzpretZavegepant Hcl17$18,317
TopamaxTopiramate13$16,028
ReyvowLasmiditan Succinate26$15,445
Lacosamide60$7,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret, Eliquis$129$429,170417 claims
AbbVieUbrelvy, Botox, Qulipta, Savella$1,784$388,875314 claims
UCB, Inc.Briviact, Neupro$335$51,93541 claims
Lundbeck LLCVyepti$521$29,82615 claims
SK Life Science, Inc.Xcopri$851$20,59512 claims
Lilly USA, LLCReyvow$560$15,44526 claims
Upsher-smith Laboratories LLCTopiramate$25$1,202172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Massillon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →